Over the years, much discussion has taken place on whether the transfusion of "older" red blood cell (RBC) units is associated with worse patient outcomes.This presentation will discuss what what happens to red cells during storage and look at results from more recent random controlled trials that offer evidence in the debate over the age of blood for transfusion.

Presented by: Matthew Karafin, MD, MS
Associate Medical Director, Transfusion Services
Assistant Investigator, Medical Sciences Institute
BloodCenter of Wisconsin
Assistant Porfessor of Pathology, Medical College of Wiscosnsin

This presentation is intended for physicians, nurses, pharmacists, laboratory scientists, and other members of the healthcare team involved in the care of patients with massive bleeding.

The goal of this activity is to provide medical news to physicians and other healthcare professionals in order to enhance patient care.

Upon completion of this activity, participants will be able to:

  1. Define a massive transfusion
  2. Discuss the importance of a massive transfusion protocol (MTP)
  3. Describe the impact of MTP on blood use and patient outcomes


Lisa Baumann-Kreuziger, MD, MS 
Associate Medical Director, 
BloodCenter of Wisconsin, Inc.
Assistant Investigator, Blood Research Institute
Assistant Professor, Department of Medicine/Hematology and Oncology, Medical College of Wisconsin

Disclosure: Dr. Lisa Baumann-Kreuziger has disclosed no relevant financial relationships.

Dr. Baumann-Kreuziger will be discussing the off-label use of tranexamic acid and fibrinogen concentrate.

BloodCenter of Wisconsin designates this activity for up to 0.5 hours of participation for continuing education for health professionals.